Real World Evidence Solutions Market

Real World Evidence Solutions Market Size, Share & Trends Analysis Report By Component (Services, Data Sets), By Therapeutic Area (Oncology, Cardiology), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033

Real World Evidence Solutions Market Summary

The global real world evidence solutions market size was estimated at USD 3.04 billion in 2025 and is projected to reach USD 6.04 billion by 2033, growing at a CAGR of 9.08% from 2026 to 2033. This growth is attributed to the increase in R&D spending, rising applications of real-world evidence (RWE) in various fields, support from regulatory bodies for using RWE solutions, and the growing volume of real-world data, which are anticipated to boost the market growth.

Regulatory bodies worldwide are increasingly recognizing the value of real-world evidence to supplement clinical trial data, accelerate drug approvals, and enhance patient safety monitoring. This support reduces barriers for pharmaceutical and biotech companies to adopt RWE, thereby driving market growth. Strong regulatory frameworks encourage the collection, analysis, and use of real-world data in decision-making, making RWE a standard part of healthcare research, drug development, and post-market surveillance. To support wider adoption, regulatory bodies are introducing policies and guidance that actively facilitate the practical use of RWE in regulatory submissions and post-market evaluations. For instance,

• In December 2025, the U.S. Food and Drug Administration removed a longstanding requirement that real-world evidence submitted in drug and device applications include identifiable individual patient data, allowing de-identified datasets such as registries, claims, and EHR networks to be considered on a case-by-case basis in regulatory reviews.
• In January 2025, the UK’s Medicines and Healthcare Products Regulatory Agency launched its pilot Real-World Evidence (RWE) Scientific Dialogue Programme as part of its 2024-27 Data Strategy to help innovators refine evidence-generation strategies and clarify regulatory and health-technology assessment expectations for RWE. The pilot offers confidential discussions and a “safe harbour” workshop, aiming to improve RWE methodologies and support regulatory and HTA decision-making across diverse products and disease areas.

Such regulatory efforts are strengthening the industry’s trust in real-world evidence approaches, thereby driving broader global uptake of RWE solutions.

The growing volume of real-world data is a key market driver, as the volume of health-related data continues to grow at a compound annual rate of 36%. Data from electronic health records, insurance claims, disease registries, wearables, and patient-reported outcomes is increasing in both scale and granularity. Advances in data integration, interoperability, and analytics enable RWE platforms to transform these vast datasets into meaningful, actionable insights. This allows pharmaceutical companies, payers, and healthcare providers to generate more accurate, representative, and timely evidence, supporting drug development, regulatory submissions, and value-based care initiatives.Global Real World Evidence Solutions Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global real world evidence solutions market report based on component, application, end use, therapeutic area, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)
• Services
• Data Sets
• Clinical Settings Data
• Claims Data
• Pharmacy Data
• Patient-Powered Data
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Development & Approvals
• Medical Device Development & Approvals
• Reimbursement/Coverage and Regulatory Decision Making
• Post Market Safety & Adverse Events Monitoring
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
• Clinical research
• Commercial (inclusive of marketing, etc.)
• HEOR
• Others (market access, etc.)
• Healthcare Payers
• Healthcare Providers
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiology
• Neurology
• Diabetes
• Psychiatry
• Respiratory
• Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• Israel
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more